Sebastian Breuer

Managing Director at QUESTALPHA GmbH & Co. KG

Eschenburg, Hesse, Germany

About

I lead a midsize MedTech company through phases of rapid scaling and operational evolution. Over the past five years, I have successfully doubled corporate revenue and doubled our workforce, proving that aggressive growth and organizational stability can go hand-in-hand. My approach combines deep financial grounding with a high-stakes track record in international M&A, VC fundraising, and strategic alliance management. I specialize in turning complex strategies into profitable, operational realities by bridging the gap between financial discipline and organizational leadership. Core Competencies Strategic Leadership: Corporate Strategy, Organizational Scaling, Change Management, Team Building & Retention, Operational Excellence. Corporate Development: International M&A, Venture Capital (VC) Fundraising, Due Diligence, Strategic Alliances, Licensing Agreements. MedTech & Growth: Commercialization Strategy, Market Access, Sales Growth & Optimization, International Business Development, Profitability Enhancement. Governance & Operations: Financial Grounding, Regulatory Navigation, Contract Negotiation, Stakeholder Management, Strategic Project Management.

Experience

  • Managing Director at QUESTALPHA GmbH & Co. KG
    Nov 2020 - Present · 5 yrs 9 mos

  • Chief Operating Officer at PreviPharma
    Jul 2019 - Oct 2020 · 1 yr 4 mos

  • Biotest AG (12 yrs 1 mo)
    • Vice President Business Development
      Feb 2012 - Jun 2019 · 7 yrs 5 mos

      Leading Global Business Development activities of Biotest including in- and out-licensing activities for plasma proteins, monoclonal antibodies, M&A, patents & trademarks, alliance management, and market research.

    • Director Business Development Plasma Proteins
      Jan 2010 - Feb 2012 · 2 yrs 2 mos

      Conducted (from initiation to signing and closing) Biotest Microbiology - Merck deal (€ 101 m). Plasma proteins: Responsible for business development, M&A, partnering and licensing, closed several license deals and cooperation agreements.

    • Head of Business Development Diagnostics
      Jun 2007 - Dec 2009 · 2 yrs 7 mos

      Conducted (from initiation to signing and closing) BMD (Biotest Medical Diagnostics) - BioRad deal (€ 45 m). Development and implementation of diagnostics strategy and business model. Closed cooperation and licensing agreements.

  • Program Manager Diagnostics / Principal Scientist at The Genetics Company
    Aug 2000 - May 2007 · 6 yrs 10 mos

    Head of Marketing and Sales, Head of Research and Development, Head of Production and Logistics. Implementation and launch of Alzheimer's Diagnostics business (from Abeta GmbH acquisition in 2003). The latter has been acquired through Merck/ Millipore in 2009. Alliance management, cooperation agreements with big pharma companies.